Dana-Farber Collaboration with OncoClinic, a Joint Venture between Al Faisaliah Group and Oncoclínicas&Co, will Bring World-Class Oncology to Saudi Arabia

OncoClinic, a joint venture between Al Faisaliah Group and Oncoclínicas&Co, today announced a strategic collaboration with Dana-Farber Cancer Institute, one of the world’s leading centers for cancer care, research, and education, and a National Cancer Institute-designated Comprehensive Cancer Center. As a primary teaching affiliate of Harvard Medical School, Dana-Farber integrates cutting-edge science with compassionate, patient-centered care for adults and children.

OncoClinic and Dana-Farber are committed to reducing the burden of cancer by promoting high-quality patient care, expanding access to timely diagnosis and evidence-based treatment, and strengthening local capacity through clinician education and collaborative research. Through this collaboration, Dana-Farber will serve as academic advisor to OncoClinic, providing strategic planning support, clinical program development advice, and robust interdisciplinary clinician education programs.

Building on Dana-Farber’s longstanding collaboration with Oncoclínicas&Co in Brazil, this collaboration will expand precision oncology practices, evidence-based treatments, and a patient-centered approach aligned with the highest international standards for patients in the kingdom.

“We are honored to collaborate with OncoClinic to bring world-class oncology care closer to patients and their families across the Kingdom of Saudi Arabia. Consistent with our international mission, this new collaboration will have a significant impact on patients, clinicians, and the broader healthcare community in Saudi Arabia,” said Dr. Craig Bunnell, Morse Family Chief Medical Officer, Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School.

“Saudi Arabia already has strong oncology institutions and outstanding clinicians. Our aim is not to duplicate what exists, but to strengthen it by bringing a focused, oncology-only model and the operating experience of the Oncoclínicas&Co network, supported by Dana-Farber’s academic advisory and interdisciplinary education programs,” said Dr. Mohammed Faihan Alotaibi, CEO of OncoClinic. “Together with Al Faisaliah Group, we are building a Saudi-rooted outpatient platform that expands access to timely diagnosis and evidence-based treatment, with multidisciplinary coordination at its core. We are honored to collaborate with Dana-Farber Cancer Institute and to benefit from its academic guidance and shared commitment to clinical excellence.”

The first outpatient facility in Riyadh will provide comprehensive outpatient oncology care, including diagnostics, chemotherapy, and radiotherapy. Equipped with state-of-the-art technology and led by top-tier Saudi oncologists alongside a highly skilled clinical team, the center represents a major step toward expanding access to high-quality oncology care in the region.

“Through this strategic collaboration, our physicians, nurses, pharmacists, quality and patient safety and administrative experts will work with counterparts at OncoClinic to advance the best-in-class oncology care. Our comprehensive education programs will support the continuous professional development of providers at OncoClinic,” said Dr. Otto Metzger, Associate Medical Director, International Strategic Initiatives, Dana-Farber Cancer Institute, and Assistant Professor of Medicine, Harvard Medical School.

For OncoClinic, this collaboration underscores a commitment not merely to replicate an international model, but to build a Saudi-rooted, world-class oncology ecosystem - developed with advisory support from Dana-Farber and supported by the global Oncoclínicas network. Together, this collaboration sets a new benchmark for oncology in the Kingdom and positions Saudi Arabia at the forefront of advancing life-saving innovation in the Middle East.